ArriVent BioPharma, Inc.
AVBP
$20.82
-$0.35-1.65%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.30M | 14.87M | 13.16M | 11.47M | 9.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.31M | 93.72M | 86.21M | 83.09M | 74.59M |
| Operating Income | -94.31M | -93.72M | -86.21M | -83.09M | -74.59M |
| Income Before Tax | -80.49M | -81.05M | -74.89M | -74.58M | -69.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -80.49 | -81.05 | -74.89 | -74.58 | -69.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.49M | -81.05M | -74.89M | -74.58M | -69.33M |
| EBIT | -94.31M | -93.72M | -86.21M | -83.09M | -74.59M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.57 | -9.77 | -14.68 | -24.81 | -33.57 |
| Normalized Basic EPS | -1.61 | -6.10 | -9.17 | -15.51 | -20.98 |
| EPS Diluted | -2.57 | -9.77 | -14.68 | -24.81 | -33.57 |
| Normalized Diluted EPS | -1.61 | -6.10 | -9.17 | -15.51 | -20.98 |
| Average Basic Shares Outstanding | 125.85M | 94.85M | 63.87M | 32.37M | 8.61M |
| Average Diluted Shares Outstanding | 125.85M | 94.85M | 63.87M | 32.37M | 8.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |